XORTX Therapeutics Inc. (XRTX)

US Markets · Healthcare · Biotechnology

$2.18 -1.36%

Closing price as of 2026-06-08 · Source: TEK2day Finance

1-Year Price History -11.4% over period

Key Metrics

Market Cap

$4.0M

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.